Sign in
WithdrawnNo phase

Effects of Esketamine on the Incidence of Postoperative Delirium and Postoperative Sleep Disturbance in Elderly Patients After Major Non-cardiac Surgery

Key facts

Who runs it
RenJi Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Started
1 Apr 2025
Ended
30 Sept 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Esketamine
  • 0.9 % saline
Record updated
16 May 2025
Why it stopped
The trial protocol has undergone substantial revisions, including modifications to the primary outcome measure, which fundamentally alter the original study objectives. As these changes are not compatible with the initial registration, we

Who can take part

Age
65 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (17)Hide the full registry criteria

Who can take part

  • Age ≧ 65 years
  • ASA Ⅰ-Ⅲ
  • Elective major non-cardiac surgery
  • Voluntary signed informed consent

Who cannot take part

  • Emergency or trauma surgery
  • Prior history of postoperative delirium or postoperative cognitive decline
  • People with mental illness
  • Suffering from serious central nervous system disorders such as arkinson's disease, Alzheimer's disease, etc
  • Suffering from severe systemic underlying diseases (e.g. cardiac insufficiency, malignant arrhythmia, malignant hypertension, hepatic failure, renal failure, etc.)
  • Patients with stage 3 or 4 malignant tumors, pancreatic cancer, allbladder cancer, cholangiocarcinoma and other tumors with high malignancy and poor prognosis
  • history of allergy to or contraindication to esketamine
  • Elevated intracranial pressure
  • The patient has impaired hearing or impaired vision
  • The patient is in chronic pain
  • The patient is severely malnourished
  • inability or unwillingness to complete questionnaires or clinical testing
  • Unable or unwilling to use a postoperative intravenous analgesic pump

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Postoperative delirium (POD) is a common surgical complication.It is associated with a range of negative outcomes such as delayed postoperative recovery,prolonged hospitalization,additional medical expenditures and higher mortality.

Read full original descriptionShow less

Meanwhile,sleep disorders are not only an important predisposing factor for delirium,but also one of the main symptoms of delirium.Systemic inflammatory responses caused by sleep disorders may be an important mechanism for POD.

Many studies have shown that esketamie may inhibit inflammatory factors and enhance neuroplasticity.

In summary,we felt the need to further explore the therapeutic potential of esketamine in the area of POD as well as postoperative sleep disorders.

The 2 groups in the trial

  • esketamine groupTreatment being tested

    The esketamine group patients will be received esketamine perioperatively.

    Treatment: Esketamine

  • Placebo groupPlacebo, for comparison

    The placebo group patients will be received 0.9% saline perioperatively.

    Treatment: 0.9 % saline

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effects of Esketamine on the Incidence of Postoperative Delirium and Postoperative Sleep Disturbance in Elderly Patients After Major Non-cardiac Surgery: A Multi-Center Randomized Controlled Trial
Record updated
16 May 2025